B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2527-2534

  Liu, Wei Hui ^a   Chen, Ya Yu ^a   Zhu, Shao Xing ^b   Li, Yi Ning ^a   Xu, Yi Peng ^b   Wu, Xue Jing ^a   Guo, Yi Hong ^a   Wang, Jia Liang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

B7 H4; Bladder urothelial carcinoma; ELISA; Immunohistochemistry; Soluble B7 H4; Tumor immune escape

Indexed keywords

V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; ROSETTE TEST; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY;

EID: 84908027780     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2522     Document Type: Article

References (29)

1. van Rhijn BW, Burger M, Lotan Y, et al: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56: 430-442, 2009.
2. Parkin MD, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. + T cells independent of the PD-1 receptor. J Exp Med 198: 31-38, 2003.
4. Hsu FJ and Komarovskaya M: CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother 25: 455-468, 2002.
5. Nagamori M, Kawaguchi S, Murakami M, et al: Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells. Anticancer Res 22: 3223-3227, 2002.
6. Liu X, Gao JX, Wen J, et al: B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 197: 1721-1730, 2003.
7. Sica GL, Choi IH, Zhu G, et al: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861, 2003.
8. Choi IH, Zhu G, Sica GL, et al: Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171: 4650-4654, 2003.
9. Mao YX, Chen YJ, Ge Y, et al: Recombinant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro. Acta Pharmacol Sin 27: 741-746, 2006.
10. Simon I, Zhuo S, Corra L, et al: B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66: 1570-1575, 2006.
11. Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006.
12. Krambeck AE, Thompson RH, Dong H, et al: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391-10396, 2006.
13. Tringler B, Zhuo S, Pilkington G, et al: B7-H4 is highly expressed in ductal and 1obular breast cancer. Cli Cancer Res 11: 1842-1848, 2005.
14. Zang X, Thompson RH, Al-Ahmadie HA, et al: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463, 2007.
15. Kryczek I, Wei S, Zou L, et al: Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177: 40-44, 2006.
16. Suh WK, Wang S, Duncan GS, et al: Generation and characterization of B7-H4/B7Sl/B7x-deficient mice. Mol Cell Biol 26: 6403-6411, 2006.
17. Margel D, Tal R, Golan S, et al: Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. Urology 69: 78-82, 2007.
18. Porena M, Del Zingaro M, Lazzeri M, et al: Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 84: 23-27, 2010.
19. Hinotsu S, Akaza H, Naito S, et al: Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. BJU Int 108: 187-195, 2011.
20. Järvinen R, Kaasinen E, Sankila A and Rintala E; Finn Bladder Group: Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56: 260-265, 2009.
21. Duchek M, Johansson R, Jahnson S, et al; Members of the Urothelial Cancer Group of the Nordic Association of Urology: Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57: 25-31, 2010.
22. Sobin LH, Gospodariwicz M and Wittekind C (eds): TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edition. Wiley-Blackwell, Hoboken, USA, pp 262-265, 2009.
23. Sauter G, Algaba F, Amin M, et al: Tumour of urinary system: non-invasive urothelial neoplasis. In: WHO Classification of Tumours Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Eble JN, Sauter G, Epstein JI and Sesterhenn IA (eds). IARCC Press, Lyon, 2004
24. Thompson RH, Zang X, Lohse CM, et al: Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68: 6054-6058, 2008.
25. Miyatake T, Tringler B, Liu W, et al: B7-H4 (DD-0110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106: 119-127, 2007.
26. Simon I, Katsaros D, Rigault de la Longrais I, et al: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 106: 334-341, 2007.
27. Acuto O and Michel F: CD28-mediated co-stimulation: a quantitative support for TCR signaling. Nat Rev Immunol 3: 939-95l, 2003.
28. Alegre ML, Frauwirth KA, Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1: 220-228, 2001.
29. Jiang J, Gross D, Elbaum P and Murasko DM: Aging affects initiation and continuation of T cell proliferation. Mech Ageing Dev 128: 332-339, 2007.